Clinical trials are the most reliable – and ultimately the fastest – way to translate promising laboratory science into new and better ways to treat and care for people living with ALS.

Launched in 2021, our Clinical Trial Awards help stimulate the development of new and improved therapies for ALS by providing up to $1,000,000 over 2 or 3 years to support early-stage clinical trials. These trials produce data on safety, dosing and biomarkers that are essential for moving an investigational therapy one step closer to being evaluated by the FDA. Positive results at this stage also “de-risk” the next stage of drug development, typically large clinical trials, and help attract the follow-on funding necessary to complete this work.

The application period for these awards is currently open. Interested applicants should submit a letter of intent by January 25, 2024, 5 p.m. US ET.     


For me, this grant is recognition of years of hard work. Now we will be able to run clinical trials [for] patients with ALS and ultimately use what we learn to help others suffering from the disease.”
Richard Robitaille, Ph.D.
2021 Clinical Trial Award Recipient
Help Get Us Closer to a Cure
So much progress has been made, and researchers are close to making even more breakthroughs. With your contribution, they can finish the work they’ve started and find the way to a cure for ALS.
Print Friendly and PDF